Specific concerns for Crohn's patients include: Nausea and vomiting : May exacerbate existing symptoms or lead to dehydration, particularly concerning in patients with active disease Diarrhea : Difficult to differentiate from Crohn's-related diarrhea, potentially delaying recognition of disease flares Abdominal pain : May mask or mimic Crohn's-related pain, complicating clinical assessment Reduced oral intake : Appetite suppression combined with nausea may worsen nutritional deficiencies common in IBD Additional FDA-labeled risks include: Acute gallbladder disease : Cholelithiasis and cholecystitis occur more frequently with semaglutide, particularly with rapid weight loss [12] [15] Acute kidney injury : Dehydration from gastrointestinal side effects may lead to kidney injury Pancreatitis : Patients should be monitored for severe, persistent abdominal pain, sometimes radiating to the back Rare but serious gastrointestinal adverse events reported in post-marketing surveillance include cases of bowel obstruction and ileus

CJC-1295 and Ipamorelin stimulate IGF-1 production, which plays a direct role in muscle cell growth and regeneration
BPC-157 may be suitable for a wide range of individuals, particularly those seeking to support healing processes and overall well-being under clinical guidance
PMID: 35441470 Chey WD, Hashash JG, Manning L, Chang L
Available: Bockwoldt, M., Dorothe, H., Niere, M., Gossmann, T.I., Reinartz, I., Schug, A., Ziegler, M., Heiland, I., Identification of evolutionary and kinetic drivers of NAD-dependent signaling, Proceedings of the National Academy of Sciences of the United States of America, vol
Others maintain full therapeutic doses to prevent weight regain